| |
|
|
|
|
|
|
|
Epigenetics
22nd September 2010
NHLI,
Kensington, London |
|
|
|
The first generation of epigenetic modifying
drugs (Histone deacetylase inhibitors and DNA methyl transferase
inhibitors) have now reached the market place and are rapidly proving
themselves as useful agents for a range of oncology indications. An
explosion in the amount of research being carried out in this field is
underway with a plethora of new histone and DNA modifying drug targets
being pursued for a range of therapeutic indications such as oncology,
inflammatory disorders and metabolic disease.
This SMR symposium brings together a panel of international speakers
across the breadth of research and development in the field of epigenetics
drug discovery, to present and discuss new advances and results from early
research to clinical data. Topics include the fundamental biology of
epigenetics, therapeutic opportunities and approaches, first generation
epigenetic drug case histories in oncology and the next generation of
epigenetic drugs.
|
|
|
|
What would you like to do? |
|
|
|
SORRY,
REGISTRATION IS NOW CLOSED |
|
|
|
|
